The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?

We investigated the off-patent biological market in Belgium from a policy maker’s perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator’s reach and to a concertation model with assessment and apprais...

Descripción completa

Detalles Bibliográficos
Autor principal: Wilder, Philippe Van
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069942/
https://www.ncbi.nlm.nih.gov/pubmed/33920150
http://dx.doi.org/10.3390/ph14040352
Descripción
Sumario:We investigated the off-patent biological market in Belgium from a policy maker’s perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator’s reach and to a concertation model with assessment and appraisal being mixed which results in poorly effective policy measures.

Ejemplares similares